Recent evidence has shown that inhibiting the downstream signaling of MYC through cyclin-dependent kinase (CDK) inhibitors can enhance cancer cell sensitivity to PARP inhibitors, regardless of the BRCA status, in triple-negative breast cancer (TNBC) [180]. This evidence concerns the gene MYC and cancer.